linjc16/ctgov huggingface dataset:
The Link Between the Clinical Resting Heart Rate and Sympathetic Overactivation

Study Overview
=================
Brief Summary
-----------------
It is a retrospective study with no products limitation to investigate the link between clinical resting HR and SOA. Use HR≤60bpm as control group, compare other three groups with the control group and find out the correlation between HR and SOA indexes.

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of subject informed written or oral consent Female and male aged≥ 20 to ≤ 80 years; Records on mean clinical heart rate and SOA indexes were available. Exclusion Criteria: Participation in another clinical study with an investigational product during the last 6 months; Drug intervention on heart rate 1 month prior to the inclusion; Patients with missing data in the database from the Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group1<br>RHR≤60bpm | |
| group2<br>RHR 61-70bpm | |
| group3<br>RHR 71-80bpm | |
| group4<br>RHR >80bpm | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference of HRV, BPV, LF/HF between each groups | The difference on mean sympathetic overactivation related indexes such as HRV, BPV, LF/HF between groups | 1min HR measure |
Canine-Assisted Profiling of Lung Cancer From Human Breath

Study Overview
=================
Brief Summary
-----------------
The study aims to optimize and define a reproducible and non-invasive method for canine assisted lung cancer detection, using human breath samples from patients and controls for training and testing purposes.

Official Title
-----------------
Canine-Assisted Profiling of Lung Cancer From Human Breath

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: Human breath samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy volunteers, lung cancer or other lung disease. Exclusion criteria: Other known malignancy.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lung cancer<br>Patients with lung cancer | Other: Human breath samples<br> <br> |
| Other: Controls<br>Controls being either healthy or having other lung disease | Other: Human breath samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity for lung cancer, of canines sniffing breath samples | Patients and Controls deliver breath samples to be presented for dogs in a Remote facility. Outcomes will be reported for individual dogs and combinations of dogs. | 2 years |
Respiratory Function and Walking Capacity in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
Multiple sclerosis (MS) is a chronic progressive neurological disease. Respiratory dysfunction due to weakness in the respiratory musculature has been described in MS. This leads to increased morbidity and mortality in late stages of the disease. It is possible that respiratory dysfunction influence physical fitness in earlier stages as well. Walking disability and fatigue causes significant impact on health in patients with MS, even in earlier stages. The hypothesis is that there is a relationship between respiratory function, walking capacity and fatigue and that daily deep breathing exercise during two months will improve respiratory function, walking capacity and fatigue.

Detailed Description
-----------------
Presented above.

Official Title
-----------------
Respiratory Function and Walking Capacity in Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis, Respiratory; Disorder, Functional, Impaired, Difficulty Walking

Intervention / Treatment
-----------------
* Other: Breathing exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inhabitant in Orebro county, Sweden, that are diagnosed with MS according to the revised McDonald criteria and registered in the Swedish MS-registry with EDSS (Expanded disability status scale) score in the interval ≥ 3.0 - ≤ 7.0. Participants must understand verbal and written information and must be relapse free ≥ 3 months prior to inclusion. Exclusion Criteria: Patients with diseases that may have influence on walking ability and respiratory function (other than MS). Such conditions include heart and lung diseases, orthopedic disorders, patients recently subjected to surgery, and non-MS related neurological dysfunction.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Breathing exercises<br>Daily deep breathing exercises during two month | Other: Breathing exercises<br>* Breathing exercises with positive expiratory pressure.<br>|
| No Intervention: Control<br>Control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory muscle strength | Maximum expiratory pressure | Two months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple sclerosis, Self-assessment, Physical endurance, Respiratory function, Fatigue
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if an intervention of antioxidants(vitamin E, selenium and lycopene) can change (reduce) prostate tumor size and alter certain markers that can affect tumor growth and prostate cancer aggressiveness.

Official Title
-----------------
A Randomized, Double-Blind Study of Combination Vitamin E, Selenium and Lycopene vs. Placebo in Men Undergoing Radical Prostatectomy for Prostate Cancer

Conditions
-----------------
Cancer of the Prostate, Prostate Cancer, Prostatic Neoplasms

Intervention / Treatment
-----------------
* Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of a Gleason score > or = to 7 adenocarcinoma of the prostate At least 30% of one core involved Radical prostatectomy planned Willingness to discontinue use of supplements at least 4 weeks prior to study intervention (for subjects using vitamin E, selenium or lycopene at time of consent) ability and willingness to consume study intervention for 6 - 8 weeks prior to radical prostatectomy. Exclusion Criteria: Previous treatment for prostate cancer Current use of finasteride or dutasteride

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy. | Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E<br>* Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU<br>|
| Placebo Comparator: 2<br>This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy. | Drug: Placebo<br>* Twice a day with meals.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the impact of combination Vitamin E, Selenium and Lycopene on prostate tumor size and to study certain markers in blood and prostate tissue which affect prostate tumor growth or shrinkage. |  | Blood samples will be collected prior to intervention and 8 weeks later , prior to surgery. Prostate tissue will be harvested at time of surgery, after the prostate has been removed. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin E, Male Urogenital Diseases, Antioxidants, Vitamin D, Lycopene, Selenium
ACAM2000® Myopericarditis Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions. Primary Objective: - To document the natural history of confirmed, probable, suspected, and subclinical myocarditis and pericarditis (myopericarditis) following ACAM2000® vaccination. Other Pre-defined Objective: - To look for potential predictive factors for the prognosis of myopericarditis following ACAM2000® vaccination.

Detailed Description
-----------------
All participants will have received previous vaccination with ACAM2000 but will not receive any vaccination as part of the registry. All participants enrolled in the registry will be followed for 2 up to 5 years (depending on whether there are persisting signs and symptoms of myopericarditis).

Official Title
-----------------
ACAM2000® Myopericarditis Registry

Conditions
-----------------
Myocarditis, Pericarditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals who are current or former members of the active duty, Reserve, or National Guard, from any branch of service Documented vaccination with ACAM2000® vaccine Meet one of the case definitions for suspect, probable, confirmed or subclinical myopericarditis. Exclusion Criteria: Individuals not meeting at least one of the case definitions for myopericarditis will not be entered into the Registry.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Entire registry group<br>Participants with potential myopericarditis cases referred to the Registry | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of confirmed, probable, suspected, and subclinical cases of myopericarditis, categorized by time since vaccination |  | 2 years after enrollment or after the last symptoms or positive findings | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myocarditis, Pericarditis, Vaccinia virus, ACAM2000®, Smallpox vaccine
Statement of Care of Anemia in Delivering Patients at Nord Franche-Comte Hospital

Study Overview
=================
Brief Summary
-----------------
Anemia is a common pregnancy condition that has multiple origins. Its frequency and severity seem to be increasing, despite the existing management recommendations and the awareness of health professionals. The objective of this study is to make a statement of this pathology within our establishment, to evaluate the proportion of patients presenting this pathology and to highlight possible risk factors.

Official Title
-----------------
Statement of Care of Anemia in Delivering Patients at Nord Franche-Comte Hospital

Conditions
-----------------
Pregnancy Anemia

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years Delivery at Nord Franche-Comte Hospital Delivery ≥ 32 weeks of amenorrhea Informed patient and non-opposition of participation Exclusion Criteria: Protected adults (Patients under guardianship, curatorship, safeguard of justice or under family authorization) Medical interruption of pregnancy Patients with fetal death in utero or neonatal death Minor patients Premature delivery before 32 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|questionnaire post delivery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimation of the proportion of patients presenting anemia during delivery | Percentage of patients with hemoglobin less than 10.5 g/dl at entry into the delivery room | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors underlying anemia during delivery with a large questionnaire | Link between presence or absence of anemia and type of follow-up (gynecological or midwife, anemia during pregnancy and iron supplementation strategy and compliance), living conditions (geographical origin, socioeconomic situation, diet) and comorbidities | 6 month |
Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
The investigators performed a 12-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of chungkookjang on improvement of metabolic syndrome. The investigators measured decrement of body fat parameters, including Body Fat Mass, Percent Body Fat, Fat Free Mass, Weight and BMI(body mass index), and monitored their blood pressure.

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: Chungkookjang
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females 18-29 years old BMI(body mass index) ≥ 23 kg/m2 or WC(Waist Circumference) ≥ 90(men), WC(Waist Circumference) ≥ 85(women) Able to give informed consent Exclusion Criteria: Allergic or hypersensitive to any of the ingredients in the test products The diagnosis of type 1 and type 2 diabetes or fasting glucose ≥ 126mg/dL Systolic pressure ≥ 160mmHg, diastolic pressure ≥ 100mmHg History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery History of alcohol or substance abuse Participation in any other clinical trials within past 2 months Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chungkookjang<br>Chungkookjang(35g/day) | Dietary Supplement: Chungkookjang<br> <br> * Other names: Chungkookjang(35g/day);Dietary Supplement: Placebo<br> <br> * Other names: Placebo(35g/day);|
| Placebo Comparator: Placebo<br>Placebo(35g/day) | Dietary Supplement: Chungkookjang<br> <br> * Other names: Chungkookjang(35g/day);Dietary Supplement: Placebo<br> <br> * Other names: Placebo(35g/day);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Body Fat Mass | Body Fat Mass was measured in study visit 1(0 week) and visit 3(12 week). | 12 weeks | 
| Changes in Percent Body Fat | Percent Body Fat was measured in study visit 1(0 week) and visit 3(12 week). | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Glucose | Glucose was measured in study visit 1(0 week) and visit 3(12 week). | 12 weeks | 
| Changes in Cholesterol | Cholesterol was measured in study visit 1(0 week) and visit 3(12 week). | 12 weeks |
The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study

Study Overview
=================
Brief Summary
-----------------
Screening programs have been associated with a substantial reduction in colorectal cancer (CRC) mortality through endoscopic resection of preneoplastic lesions and detection of early-stage invasive cancers. In March 2020, the World Health Organization declared as a pandemic the outbreak of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. Since then, the SARS-CoV-2 have never stopped spreading, causing an unprecedented situation with highly restrictive considerations to be adopted by the majority of countries worldwide. Health-care facilities have been making an enormous effort to assist patients affected by COVID-19, while adopting measures to maintain a safe environment for patients and healthcare professionals. As a result, the usual workflow in endoscopy departments changed dramatically, leading to an increase in cancelled procedures, probably increasing the future burden of Colorectal Cancer due to delays in diagnosis.

Official Title
-----------------
The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: Colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
patients who underwent colonoscopy between the 1st October 2020 and the 31st December 2020 (pandemic cohort) patients who underwent colonoscopy between the 1st October 2019 and the 31st December 2019 (pre-pandemic cohort)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Colonoscopy|Pt. underwent colonoscopy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colorectal Cancer prevention | To investigate the impact of COVID-19 pandemic on Colorectal Cancer prevention on a global scale. | 3 months |
A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
To demonstrate the bioequivalence of a Olostar Tab versus two co-administered reference IMPs Olmetec and Crestor.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Olostar Tab.
* Drug: Co-administration of Olmetec and Crestor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI ≥ 18.5 and ≤ 30.0 kg/m2. No clinically significant findings in a 12-lead electrocardiogram (ECG) Age 18-60 years at screening Exclusion Criteria: History of severe allergy or allergic reactions to the IMPs or related drugs History of serious clinical illness that can impact fate of drugs including major surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AB<br>Olostar Tab. followed by Olmetec and Crestor | Drug: Olostar Tab.<br> <br> Drug: Co-administration of Olmetec and Crestor<br> <br> |
| Experimental: BA<br>Olmetec and Crestor followed by Olostar Tab. | Drug: Olostar Tab.<br> <br> Drug: Co-administration of Olmetec and Crestor<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC |  | 0 72hr | 
| Cmax |  | 0 72hr |
Neutrophil Gelatinase-associated Lipocalin as a New Biomarker to Detect Acute Kidney Injury in Postoperative Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Observational study aimed to test the ability of Neutrophil Gelatinase-associated Lipocalin (NGAL) concentration in blood and urine to predict and diagnose early acute renal failure (ARF) in patients after cardiac surgery with/without Cardiopulmonary bypass (CPB).

Official Title
-----------------
NGAL as a Marker of Acute Kidney Injury After Cardiac Surgery. Observational Study

Conditions
-----------------
Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women over 18 years proposed for cardiac surgery with / without CPB. Accepting to participate in the study, with informed consent signed by the patient, guardian or family member. Exclusion Criteria: Patients < 18 years. Patients do not agree to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |